Upgrade to SI Premium - Free Trial

Pfizer (PFE) Reiterated at Overweight by Cantor Fitzgerald, "Confident PFE Can Meet its Guidance for a 5-year Revenue CAGR of at least 6%"

February 8, 2022 7:21 AM
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $75.00 price target on Pfizer (NYSE: PFE), following the company's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments Trader Talk

Next Articles